Ali Ucar Mehmet, Tombak Anıl, Dagdas Simten, Akdeniz Aydan, Ceran Funda, Neselioglu Salim, Erel Ozcan, Ozet Gulsum
Mersin University, Faculty of Medicine, Department of Hematology, Mersin, Turkey.
Ankara Numune Training and Research Hospital, Department of Hematology, Ankara, Turkey.
J Med Biochem. 2020 Sep 2;39(3):336-345. doi: 10.2478/jomb-2019-0050.
This study planned to investigate the relationship of dynamic thiol/disulfide homeostasis with the prognosis of myelodysplastic syndrome (MDS).
80 patients who had been diagnosed with MDS between 2012 and 2017 and who were older than 18 were included in the study together with 80 healthy control subjects. The MDS diagnosis was confirmed using bone marrow aspiration-biopsy immunostaining. Dynamic thiol/disulfide homeostasis and ischemia-modified albumin (IMA) levels were examined.
The average IMA (0.71±0.08 vs. 0.67±0.09; p=0.002), median disulfide (18.0 vs. 11.6; p<0.001), median disulfide/native thiol (6 vs. 3; p<0.001), and median disulfide/total thiol (5.4 vs. 2.9; p<0.001) were found higher in the MDS patients compared to control group, and the median hemoglobin, median white blood cell count, median neutrophil count, median lymphocyte count, average native thiol (290.7±48.5 vs. 371.5±103.8; p<0.001), average total thiol (328.2±48.9 vs. 393±105.5; p<0.001), and average native thiol/total thiol (%) (88.3±4.3 vs. 94.2±2.1; p<0.001) were found to below. Risk factors such as collagen tissue disease (HR:9.17; p=0.005), MDS-EB-1 (HR:10.14; p=0.032), MDS-EB-2 (HR:18.2; p=0.043), and disulfide/native thiol (HR:1.17; p=0.023) were found as the independent predictors anticipating progression to acute myeloid leukemia. In the Cox regression model, risk factors such as age (HR:1.05; p=0.002), MDS-EB-1 (HR:12.58; p<0.001), MDS-EB-2 (HR:5.75; p=0.033), disulfide/native thiol (HR:1.14; p=0.040), and hemoglobin (HR:0.64; p=0.007) were found as predictors anticipating for mortality.
We can argue that dynamic thiol/disulfide homeostasis could have significant effects on both the etiopathogenesis and the survival of patients with MDS, and it could be included in new prognostic scoring systems.
本研究旨在探讨动态硫醇/二硫键稳态与骨髓增生异常综合征(MDS)预后的关系。
选取2012年至2017年间确诊为MDS且年龄大于18岁的80例患者以及80例健康对照者纳入研究。采用骨髓穿刺活检免疫染色确诊MDS。检测动态硫醇/二硫键稳态及缺血修饰白蛋白(IMA)水平。
与对照组相比,MDS患者的平均IMA(0.71±0.08对0.67±0.09;p=0.002)、二硫键中位数(18.0对11.6;p<0.001)、二硫键/天然硫醇中位数(6对3;p<0.001)和二硫键/总硫醇中位数(5.4对2.9;p<0.001)更高,而血红蛋白中位数、白细胞计数中位数、中性粒细胞计数中位数、淋巴细胞计数中位数、平均天然硫醇(290.7±48.5对371.5±103.8;p<0.001)、平均总硫醇(328.2±48.9对393±105.5;p<0.001)和平均天然硫醇/总硫醇(%)(88.3±4.3对94.2±2.1;p<0.001)更低。发现胶原组织病(HR:9.17;p=0.005)、MDS-EB-1(HR:10.14;p=0.032)、MDS-EB-2(HR:18.2;p=0.043)和二硫键/天然硫醇(HR:1.17;p=0.023)等危险因素是预测进展为急性髓系白血病的独立预测因素。在Cox回归模型中,年龄(HR:1.05;p=0.002)、MDS-EB-1(HR:12.58;p<0.001)、MDS-EB-2(HR:5.75;p=0.033)、二硫键/天然硫醇(HR:1.14;p=0.040)和血红蛋白(HR:0.64;p=0.007)等危险因素是预测死亡的因素。
我们可以认为,动态硫醇/二硫键稳态可能对MDS患者的发病机制和生存都有显著影响,并且可以纳入新的预后评分系统。